{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:45:50Z","timestamp":1792147550532,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"Defense Health Program"},{"name":"Immunization Healthcare Branch"},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["HU00011920111"],"award-info":[{"award-number":["HU00011920111"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["Y1-AI-5072"],"award-info":[{"award-number":["Y1-AI-5072"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FDA Medical Countermeasures Initiative awards"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Widespread immunity from vaccination and infection has reduced COVID-19 morbidity and mortality, but this immunity varies across the population. Understanding how repeated antigenic exposures influence antibody responses helps to inform future vaccination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We characterized neutralizing antibody (nAb) responses in serum samples collected 1- and 6-months after XBB.1.5 vaccination from 25 healthcare workers with varying, complex histories of vaccination and reported infections. Neutralizing activity was assessed against a range of variants, from pre-Omicron to recent Omicron JN.1 sublineage, and divergent BA.3.2 variants using lentiviral pseudoviruses. Participants were stratified into 5 exposure groups based on their documented vaccination and reported infection history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>XBB.1.5 vaccination elicited broad neutralizing responses, with strong boosting against previously encountered antigens relative to vaccine-matched XBB.1.5 and newer variants. Geometric mean neutralization titers were generally comparable across exposure groups, though small subgroup sizes and considerable intragroup heterogeneity precluded definitive conclusions about the influence of prior exposure history. At 6 months, titers declined by 36\u201362% across all variants. Titers remained highest against pre-Omicron variants and were lowest against JN.1 sublineage variants, with some falling to very low levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort with extensive prior antigenic exposures, broad nAb profiles were observed following XBB.1.5 vaccination, though these responses waned substantially after 6 months. The observed waning of cross-neutralizing antibodies against emerging variants underscores the challenge of maintaining durable protection and supports the need for continued monitoring of antibody responses to guide evidence-based updates to COVID-19 vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag446","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:45:55Z","timestamp":1784202355000},"source":"Crossref","is-referenced-by-count":1,"title":["Durability and Breadth of Neutralizing Antibodies Against SARS-CoV-2 Variants Following XBB.1.5 Vaccination in a Multiply Exposed Cohort"],"prefix":"10.1093","volume":"13","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-4346","authenticated-orcid":false,"given":"Emilie","family":"Goguet","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lusvarghi","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Paz","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeza","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Vassell","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pollett","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-3266","authenticated-orcid":false,"given":"Edward","family":"Mitre","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-1289","authenticated-orcid":false,"given":"Carol D","family":"Weiss","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026080308563028700_ofag446-B1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"key":"2026080308563028700_ofag446-B2","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat Commun"},{"key":"2026080308563028700_ofag446-B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"2026080308563028700_ofag446-B4","doi-asserted-by":"crossref","first-page":"106092","DOI":"10.1016\/j.antiviral.2025.106092","article-title":"Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients","volume":"235","author":"Wu","year":"2025","journal-title":"Antiviral Res"},{"key":"2026080308563028700_ofag446-B5","author":"World Health Organization"},{"key":"2026080308563028700_ofag446-B6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026080308563028700_ofag446-B7","doi-asserted-by":"crossref","first-page":"110151","DOI":"10.1016\/j.intimp.2023.110151","article-title":"Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on wild type convalescents","volume":"119","author":"Zheng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026080308563028700_ofag446-B8","doi-asserted-by":"crossref","first-page":"1027924","DOI":"10.3389\/fimmu.2022.1027924","article-title":"The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: an observational study","volume":"13","author":"Ou","year":"2022","journal-title":"Front Immunol"},{"key":"2026080308563028700_ofag446-B9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"2026080308563028700_ofag446-B10","doi-asserted-by":"crossref","first-page":"793953","DOI":"10.3389\/fimmu.2021.793953","article-title":"Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 months after SARS-CoV-2 infection","volume":"12","author":"Rosati","year":"2021","journal-title":"Front Immunol"},{"key":"2026080308563028700_ofag446-B11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.126.6.1185","article-title":"The relative affinity of antibodies synthesized in the secondary response","volume":"126","author":"Steiner","year":"1967","journal-title":"J Exp Med"},{"key":"2026080308563028700_ofag446-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60414-9","article-title":"Cell selection by antigen in the immune response","volume":"10","author":"Siskind","year":"1969","journal-title":"Adv Immunol"},{"key":"2026080308563028700_ofag446-B13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nature13300","article-title":"Clonal selection in the germinal centre by regulated proliferation and hypermutation","volume":"509","author":"Gitlin","year":"2014","journal-title":"Nature"},{"key":"2026080308563028700_ofag446-B14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"2026080308563028700_ofag446-B15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"2026080308563028700_ofag446-B16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"key":"2026080308563028700_ofag446-B17","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.xcrm.2024.101668","article-title":"Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination","volume":"5","author":"Voss","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026080308563028700_ofag446-B18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"2026080308563028700_ofag446-B19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/infdis\/jiac332","article-title":"SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity","volume":"227","author":"Manali","year":"2022","journal-title":"J Infect Dis"},{"key":"2026080308563028700_ofag446-B20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41467-023-36250-4","article-title":"SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection","volume":"14","author":"Pusnik","year":"2023","journal-title":"Nat Commun"},{"key":"2026080308563028700_ofag446-B21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12879-021-06233-1","article-title":"Prospective assessment of SARS-CoV-2 seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers","volume":"21","author":"Jackson-Thompson","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026080308563028700_ofag446-B22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"2026080308563028700_ofag446-B23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol"},{"key":"2026080308563028700_ofag446-B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248348","article-title":"Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2","volume":"16","author":"Neerukonda","year":"2021","journal-title":"PLoS One"},{"key":"2026080308563028700_ofag446-B25","article-title":"Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants","volume":"16","author":"Li","year":"2025","journal-title":"mBio"},{"key":"2026080308563028700_ofag446-B26","doi-asserted-by":"crossref","first-page":"eadu8067","DOI":"10.1126\/scitranslmed.adu8067","article-title":"The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins","volume":"17","author":"Kumar","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026080308563028700_ofag446-B27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Roltgen","year":"2022","journal-title":"Cell"},{"key":"2026080308563028700_ofag446-B28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080308563028700_ofag446-B29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to Omicron BA.4-BA.5 bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080308563028700_ofag446-B30","doi-asserted-by":"crossref","first-page":"114520","DOI":"10.1016\/j.celrep.2024.114520","article-title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep"},{"key":"2026080308563028700_ofag446-B31","article-title":"Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability","volume":"99","author":"Li","year":"2025","journal-title":"J Virol"},{"key":"2026080308563028700_ofag446-B32","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026080308563028700_ofag446-B33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02901-25","article-title":"Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination","author":"Abbad","year":"2026","journal-title":"mBio"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag446\/69192149\/ofag446.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag446\/69192149\/ofag446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag446\/69192149\/ofag446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:56:42Z","timestamp":1785761802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag446\/8736896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag446","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,17]]},"article-number":"ofag446"}}